Daewoong inaugurated its new advanced biopharmaceutical manufacturing facility in Incheon's Songdo on November 28, aiming to contribute to the commercialization of fundamental treatments for incurable diseases.
Key points
•Advanced biopharmaceutical plant opened in Songdo
•Focus on producing clinical-grade stem cell and immune cell products
•Expand global bio network through connections with overseas hubs
The company opened a state-of-the-art biopharmaceutical plant within Incheon's Songdo International University Town, preparing for full operation. The facility features global standards in sterile manufacturing and quality control systems, focusing on producing clinical-grade stem cell and immune cell products.
Daewoong plans to complete legal approvals for the manufacture and processing of advanced biopharmaceuticals by year-end, linking its research achievements from the Yongin Bio Center with patient-focused clinical trials. The new Songdo facility will also enhance Daewoong's domestic presence while expanding its global bio network through connections with overseas hubs.
Utilizing Songdo’s infrastructure, Daewoong aims to increase open innovation collaborations with local universities, research institutions, and hospitals, and develop a cutting-edge regenerative medicine ecosystem.
